SecBot SecBot
PRESS-RELEASE ·Filed Mar 1, 2026

SEPN

Septerna, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should monitor the upcoming Phase 2b trial initiation and long-term toxicology study completion as key catalysts. Positive Phase 2 data could drive significant upside given the lack of oral targeted therapies in mast cell-driven diseases.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$28.64
T+0 close · Mar 1, 2026 · via day close
Latest settled
+7.00%
T+60 · $30.65
Vs SPY
−2.33%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 2 $28.64entry
  2. T+1 · 9mo ago −1.78%α −0.87% · $28.13
  3. T+5 · 8mo ago +1.47%α +2.67% · $29.06
  4. T+20 · 8mo ago −18.65%α −10.71% · $23.30
  5. T+60 · 6mo ago +7.00%α −2.33% · $30.65
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Septerna announced positive Phase 1 results for SEP-631, an oral MRGPRX2 negative allosteric modulator, showing robust, dose-dependent inhibition of mast cell activation with a favorable safety profile and pharmacokinetics supporting once-daily dosing. The company plans to advance SEP-631 into a Phase 2b trial for chronic spontaneous urticaria (CSU) in the second half of 2026 and explore additional mast cell-driven indications.

Key Facts

  • SEP-631 demonstrated complete inhibition of icatibant-induced skin wheal formation at doses as low as 10 mg once daily.
  • The drug was well-tolerated with an adverse event profile comparable to placebo and no serious adverse events.
  • Pharmacokinetic data show a half-life of ~24 hours, supporting once-daily oral dosing without food restrictions.
  • Phase 2b trial in chronic spontaneous urticaria (CSU) planned for second half of 2026, pending toxicology study completion.
  • Additional development planned for chronic inducible urticaria and evaluation in atopic dermatitis, interstitial cystitis, migraine, and asthma.

Financial Impact

No direct financial impact reported; clinical milestone de-risks development and supports valuation upside.

pipeline valueR&D trajectoryinvestor sentiment

Risk Factors

  • Phase 1 results in healthy volunteers may not translate to efficacy in CSU patients.
  • Regulatory delays or safety signals in long-term toxicology studies could postpone Phase 2 initiation.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3246935

US Market Status

Market Closed · Opens Wed (12h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 1, 2026